Cytogenetic and Genome Research

Cui R.a· Chen P.a· Wang Y.a· Lu R.a· Ji M.b· Hou P.a· Qu Y.a,c

Author affiliations

aKey Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
bCenter for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
cDepartment of Radio Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: January 07, 2022
Accepted: April 25, 2022
Published online: June 02, 2022

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 3

ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)

For additional information: https://www.karger.com/CGR

Abstract

RAD21 plays multiple roles in numerous cancers. In breast cancer (BC), a high level of RAD21 correlates with poor disease outcomes and resistance to chemotherapy. However, data regarding RAD21 promoter methylation in BC tissue and its correlation with clinical outcomes in patients with BC remain limited. Here, we investigated the clinicopathological features associated with the methylation status of RAD21 in BC to figure out its possible role in pathogenesis and the formation of breast carcinogenesis. The methylation status of the RAD21 gene was significantly associated with better clinical outcomes in patients with BC.

© 2022 S. Karger AG, Basel

References Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. Cavalli LR. Molecular markers of breast axillary lymph node metastasis. Expert Rev Mol Diagn. 2009;9:441–54. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen. 2017;58:235–63. Cheng H, Zhang N, Pati D. Cohesin subunit RAD21: From biology to disease. Gene. 2020;758:144966. Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020;78:1070–85. Delmonico L, Alves G, Bines J. Cell free DNA biology and its involvement in breast carcinogenesis. Adv Clin Chem. 2020;97:171–223. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014;16:428. Duffy MJ, Walsh S, McDermott EW, Crown J.Biomarkers in Breast Cancer: Where Are We and Where Are We Going? Adv Clin Chem. 2015;71:1–23. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical Use of Biomarkers in Breast Cancer: Updated Guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–98. Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7:3–23. Guttery DS, Blighe K, Page K, Marchese SD, Hills A, Coombes RC, et al. Hide and seek: tell-tale signs of breast cancer lurking in the blood. Cancer Metastasis Rev. 2013;32:289–302. Ioannidou A, Zachaki S, Karakosta M, Daraki A, Roussou P, Manola KN. Cohesin RAD21 Gene Promoter Methylation in Patients with Chronic Lymphocytic Leukemia. Cytogenet Genome Res. 2018;154:126–31. Li G, Hu J, Hu G. Biomarker Studies in Early Detection and Prognosis of Breast Cancer. Adv Exp Med Biol. 2017;1026:27–39. Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2017;17:152–63. Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014;18:273–84. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52:56–73. Patani NR, Dwek MV, Douek M. Predictors of axillary lymph node metastasis in breast cancer: a systematic review. Eur J Surg Oncol. 2007;33:409–19. Pati D, Zhang N, Plon SE. Linking sister chromatid cohesion and apoptosis: role of Rad21. Mol Cell Biol. 2002;22:8267–77. Porkka KP, Tammela TL, Vessella RL, Visakorpi T. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer. 2004;39:1–10. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016;127:407–14. Seregni E, Coli A, Mazzucca N. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S15–22. Severin DM, Leong T, Cassidy B, Elsaleh H, Peters L, Venter D, et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys. 2001;50:1323–31. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. Siow ZR, De Boer RH, Lindeman GJ, Mann GB. Spotlight on the utility of the Oncotype DX(®) breast cancer assay. Int J Womens Health. 2018;10:89–100. Sopik V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res Treat. 2021;186(2):497–507. Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic Markers in Triple-Negative Breast Cancer. Clin Breast Cancer. 2018;18:e841–50. Syed YY. Oncotype DX Breast Recurrence Score(®): A Review of its Use in Early-Stage Breast Cancer. Mol Diagn Ther. 2020;24:621–32. Vagnarelli P, Morrison C, Dodson H, Sonoda E, Takeda S, Earnshaw WC. Analysis of Scc1-deficient cells defines a key metaphase role of vertebrate cohesin in linking sister kinetochores. EMBO Rep. 2004;5:167–71. Valdeolmillos AM, Viera A, Page J, Prieto I, Santos JL, Parra MT, et al. Sequential loading of cohesin subunits during the first meiotic prophase of grasshoppers. PLoS Genet. 2007;3:e28. Wang J, Zhao H, Yu J, Xu X, Jing H, Li N, et al. MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Sci. 2021;112(2):575–88. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602. Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7. Xu H, Balakrishnan K, Malaterre J, Beasley M, Yan Y, Essers J, et al. Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice. PLoS One. 2010;5:e12112. Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, McKay MJ, et al. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Res. 2012;14:R69. Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, et al. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. Nucleic Acids Res. 2016;44:558–72. Zhou B, Guo R. Genomic and regulatory characteristics of significant transcription factors in colorectal cancer metastasis. Sci Rep. 2018;8:17836. Zhu S, Zhao L, Li Y, Hou P, Yao R, Tan J, et al. Suppression of RAD21 Induces Senescence of MDA-MB-231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c-Myc Downregulation. J Cell Biochem. 2016;117:1359–69. Article / Publication Details

First-Page Preview

Received: January 07, 2022
Accepted: April 25, 2022
Published online: June 02, 2022

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 3

ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)

For additional information: https://www.karger.com/CGR

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.